Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
About Sumitomo Pharma America
We tackle unmet patient needs in the crucial fields of psychiatry and neurology, oncology, urology, women's health, rare diseases, and cell and gene therapies.
We unlock innovative science and solutions through cutting-edge technology. Advanced in-house technology platforms and data analytics capabilities de-risk and optimize clinical and commercial programs to accelerate insights in science, research, and discovery.
Advocating for Patients
We reimagine what’s possible We see people as more than the conditions they are managing. We are unwavering in our promise to advocate for patients and their families on the things that matter most to them. This promise is central to everything we do as we pursue unprecedented medical innovation.
We are building on a legacy With Sumitomo Pharma's 125-year legacy as our foundation, Sumitomo Pharma America was formed through the consolidation of Sumitomo Pharma’s US affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing.
166 articles about Sumitomo Pharma America
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer, is now available through authorized specialty distributors. “Myovant has been focused on ens
In a release issued under the same headline earlier by Myovant Sciences, please note that in the first paragraph of the release, the presentation time should be 2:50 p.m. Eastern Time, not 2:50 p.m.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D.
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
Myovant Sciences’ stock rocketed 22% on news it was partnering with Pfizer to develop and commercialize relugolix for prostate cancer and women’s health.
The U.S. Food and Drug Administration has approved several drugs and medical devices in the last week. Here’s a look.
Myovant's oral Orgovyx beat out Abbvie's injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2020 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stoc
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
FDA Priority Review of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer on track for decision by December 20, 2020 target action date
Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2020, ended September 30, 2020. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020. Investors and the general public may access a live
Myovant’s Relugolix Retains Strong Probability of FDA Approval Despite Equivalence for Castration Resistance-Free Survival
Myovant is a healthcare company developing innovative treatments for women’s health and prostate cancer. Myovant is currently evaluating their lead gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, in late-stage clinical programs for uterine fibroids, endometriosis, and prostate cancer.
10/26/2020It was another busy week for clinical trial updates and news. Here’s a look.
10/22/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts and investors, Mr. Crowe will be responsible for developing and implementing a comprehensive and strategic global investor relations program. He will report to Frank Karbe, Myovant’s president an
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids has been accepted for review by